Table 2.
Baseline characteristics of advanced HCC patients with cohort 2 (patients without both MVI and EHM)
| Unmatched |
Matched |
|||||
|---|---|---|---|---|---|---|
| HAIC (n = 89) | sorafenib (n = 492) | SMD | HAIC (n = 76) | sorafenib (n = 76) | SMD | |
| Mean age, years | 70.0 | 71.3 | 0.160 | 70.3 | 71.6 | 0.160 |
| Male gender | 69 (77.5) | 384 (78.0) | 0.013 | 60 (78.9) | 57 (75.0) | −0.094 |
| HCV positive | 51 (57.3) | 303 (61.6) | −0.087 | 42 (55.3) | 45 (59.2) | −0.080 |
| HBV positive | 14 (15.7) | 60 (12.2) | 0.102 | 12 (15.8) | 13 (17.1) | −0.035 |
| Alcohol abuse | 6 (6.7) | 32 (6.5) | 0.010 | 6 (7.9) | 4 (5.3) | 0.106 |
| Size of intrahepatic lesion >50 mm1 | 11 (12.8) | 66 (13.5) | −0.020 | 11 (14.5) | 16 (21.1) | −0.173 |
| Number of intrahepatic lesions >71 | 51 (59.3) | 219 (44.6) | 0.297 | 46 (60.5) | 44 (57.9) | 0.054 |
| Child-Pugh class A1 | 53 (63.9) | 428 (87.5) | 0.574 | 51 (67.1) | 51 (67.1) | 0.000 |
| AFP >400 ng/mL1 | 34 (38.2) | 167 (33.9) | 0.089 | 32 (42.1) | 32 (42.1) | 0.000 |
| Number of TACEs >21 | 42 (51.9) | 185 (38.5) | 0.272 | 39 (51.3) | 41 (53.9) | −0.053 |
Data are presented as the mean or n (%). AFP, alfa-fetoprotein; EHM, extrahepatic metastasis; HAIC, hepatic arterial infusion chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, macrovascular invasion; SMD, standardized mean difference; TACE, transarterial chemoembolization.
1
Size of intrahepatic lesion, number of intrahepatic lesions, Child-Pugh class, AFP, and number of TACEs were matched in cohort 2.